Sign in Subscribe
Vaccines

Johnson & Johnson Prepares Largest COVID-19 Vaccine Trial Amid Fierce Competition

Strategic Insights

— 2 min read

As COVID-19 vaccines enter critical phase 3 trials, Johnson & Johnson is gearing up for the largest study yet, aiming to enroll 60,000 participants. This massive trial will kick off next month and is set to surpass the enrollment of rival vaccine makers Moderna and Pfizer, who have already signed up tens of thousands of participants. Despite the progress, concerns have been raised about the representation of minority groups in Moderna's trial, highlighting the ongoing efforts to address disparities in vaccine distribution. Amidst the competitive landscape, AstraZeneca's vaccine is also in phase 3 testing in multiple countries, including the U.K., Brazil, and South Africa.

Key Takeaways:

  • Johnson & Johnson will lead the largest COVID-19 vaccine trial, enrolling 60,000 participants, surpassing Moderna and Pfizer's enrollment numbers.
  • The trial will test J&J's vaccine, Ad26.COV2.S, against placebo to determine its ability to reduce moderate to severe COVID-19.
  • Investigators have expressed concerns about the underrepresentation of minorities in Moderna's trial, underscoring the need for diversity in vaccine distribution.
  • AstraZeneca's vaccine is also progressing through phase 3 trials in the U.K., Brazil, and South Africa, with approximately 8,000 participants enrolled in the U.K.
  • Multiple players, including Novavax and the Sanofi-GlaxoSmithKline partnership, are involved in the hunt for a COVID-19 vaccine.
  • Governments worldwide are negotiating supply deals with companies like J&J, Moderna, and AstraZeneca in anticipation of successful vaccine candidates.

Statistics:

  • Johnson & Johnson plans to enroll 60,000 participants in its phase 3 trial.
  • Moderna has already enrolled 8,374 participants in the first three weeks of its study.
  • Pfizer has signed up more than 11,000 people to date.
  • AstraZeneca has enrolled approximately 8,000 participants in the U.K. and 3,000 in Brazil out of an expected 10,000 and 10,500 participants, respectively.
  • The U.S. government has secured agreements for 800 million vaccine doses.
  • Europe has signed a pact for 400 million doses with AstraZeneca and is in advanced discussions with several other companies.

Sources:

  • ClinicalTrials.gov (ct2/show/NCT04505722)
  • Pfizer (https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-share-positive-early-data-lead-mrna)
  • CNN (https://www.cnn.com/2020/08/18/health/vaccine-trial-progress-moderna-volunteers/index.html)
  • Politico (https://twitter.com/ZacharyBrennan/status/1293934628072501250)
  • FiercePharma (https://www.fiercepharma.com/pharma/novavax-inks-1-6b-warp-speed-deal-to-support-covid-19-vaccine-phase-3-testing-manufacturing)

Read more